UnknownPhase 1/2

Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease

South Korea15 participantsStarted 2013-05

Plain-language summary

The purpose of clinical trials is to evaluate safety and tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells as a treatment for Patients with Parkinson's disease.

Who can participate

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Female patients with idiopathic or primary Parkinson's disease
✓. Hoehn and Yare (HY) stage III or IV
✓. more than 33% improvement Part III UPDRS score after one injection of levodopa in the morning
✓. Patients aged less than 70
✓. Great decrease of dopamine uptake in putamen, particularly posterior part, in Positron emission tomograph(PET) before surgery

Exclusion criteria

✕. Atypical or secondary parkinsonism
✕. Medical history of severe depression with Beck Depression Inventory(BDI) scores greater than 30
✕. Psychological disorders (illusion, delusion, schizophrenia)
✕. Dementia with K-MMSE(Korean mini-mental state examination) scores less than 24
✕. Epilepsy
✕. Medial history of brain surgery
✕. Medical history of other brain diseases
✕. Hemorrhagic tendency

What they're measuring

Presence or absence of cancer foramtion and infection

Timeframe: 5 years

Trial details

NCT IDNCT01860794

SponsorBundang CHA Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04

Contact for this trial

Sang Sup Chung, M.D., Ph.D.

82-31-780-5261 jmoon@cha.ac.kr

View on ClinicalTrials.gov More Idiopathic Parkinson Disease trials